FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	.C. 20549
---------------	-----------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response	: 0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL,									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>Ciaffoni Joseph</u>				INC COLL									X Director				10% O	wner	
(Last)	(F	irst) (N	/iddle)			<u> </u>								X	Office below	icer (give title ow)		Other ( below)	specify
C/O COLLEGIUM PHARMACEUTICAL, INC.					3. Date of Earliest Transaction (Month/Day/Year) 08/10/2020								President and CEO						
100 TECHNOLOGY CENTER DRIVE				00/1	00/10/2020														
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) STOUG	HTON M	A 0	2072											X	Form	filed by One	e Rep	orting Pers	on
															Form Perso	filed by Mo	re thai	n One Rep	orting
(City)	(S	tate) (Z	ip)																
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of	, or E	Benefic	ially	Own	ed			
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)				Execution Date,			3. Transaction Code (Instr. 8)  4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)				4 and Securi Benefi		ties cially Following	Form (D) o	: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code V An		Amount	(A) or (D)		e	Transaction(s) (Instr. 3 and 4)				(1130.4)
Common Stock 08/10/2				2020				F		1,386(1)	1,386 <sup>(1)</sup> D		3.89	190,018			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	Code ( 8)	ransaction of Code (Instr. Derivative		rative rities sired r osed ) 1. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date		7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)  Amoun or Numbe of Title Shares		-		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

## **Explanation of Responses:**

1. Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

## Remarks:

/s/ Paul Brannelly as Attorney-08/12/2020 In-Fact For Joseph Ciaffoni

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.